menu
    • menu
    [{"orgOrder":0,"company":"SpectrumX","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"SPX-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpectrumX \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX \/ Undisclosed"},{"orgOrder":0,"company":"SpectrumX","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"SPX-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpectrumX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SpectrumX \/ Undisclosed"},{"orgOrder":0,"company":"SpectrumX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SPX-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpectrumX \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX \/ Inapplicable"},{"orgOrder":0,"company":"SpectrumX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SPX-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"SpectrumX \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by SpectrumX

    Menu

    SpectrumX

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    SpectrumX

    United Kingdom arrow
    Interphex
    Not Confirmed

    SpectrumX

    United Kingdom arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPX-001

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    SpectrumX Confirms Next Step in Clinical Development of Respiratory Drug Candidate SPX-001 After MHRA Meeting

    Details : SPX-001 is SpectrumX’s nebulised respiratory infection drug candidate, based on the Company’s licensed hypochlorous acid (HOCl)-based SPC-069 drug substance, which is believed to have broad-spectrum antipathogenic properties.

    Product Name : SPX-001

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    November 24, 2022

    Lead Product(s) : SPX-001

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    SpectrumX

    United Kingdom arrow
    Interphex
    Not Confirmed

    SpectrumX

    United Kingdom arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPX-001

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase I

    Sponsor : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    SpectrumX Reaches Partnership Agreement on Human Volunteer Study for Ground-breaking Respiratory Infection Dru...

    Details : Start-up agreement is major step forward in readiness to conduct Phase 1b clinical trial of Company’s HOCl-based respiratory infection drug candidate, SPX-001.

    Product Name : SPX-001

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    September 20, 2022

    Lead Product(s) : SPX-001

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Sponsor : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    SpectrumX

    United Kingdom arrow
    Interphex
    Not Confirmed

    SpectrumX

    United Kingdom arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPX-001

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    SpectrumX Confirms Scientific Advice Meeting With MHRA, Proposed Timeline for Human Clinical Trials for Ground...

    Details : SpectrumX has confirmed scientific advice meeting with MHRA and will discuss the available data supporting the commencement of human trials with SPX-001 (Hypochlorous Acid) protocol for Phase Ib human volunteer study, prior to submission of CTA submissio...

    Product Name : SPX-001

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 08, 2022

    Lead Product(s) : SPX-001

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    SpectrumX

    United Kingdom arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    SpectrumX

    United Kingdom arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SPX-001

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Preclinical

    Sponsor : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    SpectrumX Partners With Leading UK Specials Group to Accelerate Production of Anti-Pathogenic Drug for Clinica...

    Details : SPX-001 is a potential novel treatment, based on hypochlorous acid (HOCl), for respiratory infections and is a new drug candidate for Europe with broad-spectrum anti-pathogenic properties.

    Product Name : SPX-001

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    March 08, 2022

    Lead Product(s) : SPX-001

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Preclinical

    Sponsor : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth